

第30回日本心血管インターベンション治療学会学術集会

CVIT 2022

The 30th Annual Meeting of the Japanese Association of Cardiovascular Intervention and Therapeutics



会期 | 2022年7月21日(木)～23日(土)

会場 | ハイブリッド形式
パシフィコ横浜ノース・Web配信

会長 | 伊莉 裕二 東海大学医学部内科学系循環器内科

カテーテルインターベンションの真価



シンポジウム 41

日本の下肢静脈瘤治療、世界の下肢静脈瘤治療

Treatment of varicose veins in Japan, and treatment of varicose veins in the world

今井崇裕

西の京病院 血管外科

Takahiro Imai

Department of Vascular Surgery, Nishinokyo Hospital, Nara, Japan

ABSTRACT

Currently, the standard treatment for varicose veins in Japan is Endovenous ablation, which has been covered by national health insurance in Japan in 2011.

Cyanoacrylate closure (CAC) is one of non-thermal non-tumescent treatments for varicose veins, and the VenaSeal Closure System, a commercially available CAC, was subsequently approved by national health insurance in Japan in 2019. Domestic treatment of varicose veins is becoming less invasive. The same tendency applies to treatment overseas. Internationally, there are various minimally invasive treatments such as NTNT treatment from Turkey using n-butyl- cyanoacrylate (NBCA), ClariVein that combines polydocasclerol with mechanical stimulation, and VBAS that adds a device that closes veins to a sclerosing agent. It is expected that the optimal treatment for varicose veins in Japan will be selected according to the patient's condition.